Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Janae Romeo"'
Autor:
William J. Chapin, Jacob E. Till, Wei-Ting Hwang, Jennifer R. Eads, Thomas B. Karasic, Peter J. O'Dwyer, Charles J. Schneider, Ursina R. Teitelbaum, Janae Romeo, Taylor A. Black, Theresa E. Christensen, Colleen Redlinger Tabery, Amanda Anderson, Megan Slade, Michael LaRiviere, Stephanie S. Yee, Kim A. Reiss, Mark H. O'Hara, Erica L. Carpenter
Publikováno v:
JCO precision oncology. 6
PURPOSE Pancreatic ductal adenocarcinoma (PDAC) is associated with a poor prognosis. Multianalyte signatures, including liquid biopsy and traditional clinical variables, have shown promise for improving prognostication in other solid tumors but have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b5c3a9a69c1348cb58b0dfe0498373
https://pubmed.ncbi.nlm.nih.gov/35939771
https://pubmed.ncbi.nlm.nih.gov/35939771
Autor:
Zain M. Hannan, Kim A. Reiss, Natallia Izgur, Ursina R. Teitelbaum, Susan M. Domchek, Robert H. Vonderheide, Charles Schneider, Thomas B. Karasic, Katherine L. Nathanson, Gregory L. Beatty, Rosemarie Mick, Rashmi Tondon, Stacy Cowden, Mark H. O'Hara, Janae Romeo, Traci Southwell, Max M. Wattenberg
Publikováno v:
Journal of Clinical Oncology. 39:2497-2505
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline BRCA1 or BRCA2 pathogenic variant (PV). This investigator-initiated, single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f04f815e04ccf12910bb0a391cc45f96
https://doi.org/10.1200/jco.21.00003
https://doi.org/10.1200/jco.21.00003
Autor:
Kim A, Reiss, Rosemarie, Mick, Mark H, O'Hara, Ursina, Teitelbaum, Thomas B, Karasic, Charles, Schneider, Stacy, Cowden, Traci, Southwell, Janae, Romeo, Natallia, Izgur, Zain M, Hannan, Rashmi, Tondon, Katherine, Nathanson, Robert H, Vonderheide, Max M, Wattenberg, Gregory, Beatty, Susan M, Domchek
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(22)
Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germlineEligible patients had advanced PC; germline (g) or somatic (s) PVs inOf 46 enrolled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5505b56c3409d8d72a5acf4a4c07625a
https://pubmed.ncbi.nlm.nih.gov/33970687
https://pubmed.ncbi.nlm.nih.gov/33970687
Autor:
Colleen Redlinger, Taylor A. Black, Stephanie S. Yee, David Issadore, Arjun Raj, Jina Ko, Neha Bhagwat, Erica L. Carpenter, Ben Z. Stanger, Mark H. O'Hara, Janae Romeo
Publikováno v:
Lab on a chip. 17(18)
The use of microtechnology for the highly selective isolation and sensitive detection of circulating tumor cells has shown enormous promise. One challenge for this technology is that the small feature sizes – which are the key to this technology's
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::659d3fac3eab9fb4c675e0eaf92b339a
https://pubmed.ncbi.nlm.nih.gov/28809985
https://pubmed.ncbi.nlm.nih.gov/28809985
Autor:
Mehran Makvandi, Janae Romeo, Kara N. Maxwell, Mary Jane Fuhrer, Erica L. Carpenter, Kim A. Reiss Binder, Peter J. O'Dwyer, Katherine L. Nathanson, Thomas B. Karasic, Susan M. Domchek, Gregory L. Beatty, Ursina R. Teitelbaum, Stacy Cowden, Rosemarie Mick, Mark H. O'Hara, David A. Mankoff, Charles Schneider, Austin R. Pantel
Publikováno v:
Cancer Research. 79:CT234-CT234
Background: PARP inhibitors have activity in multiple BRCA-related malignancies and have recently demonstrated dramatic efficacy as a maintenance strategy for platinum-sensitive ovarian cancer. Between 5-8% of patients with pancreatic cancer (PC) hav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f054be6ce0f36d0cd1f44c2e9c69ee9f
https://doi.org/10.1158/1538-7445.am2019-ct234
https://doi.org/10.1158/1538-7445.am2019-ct234